Not yet recruitingPhase 4NCT07010302
Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD
Studying Neuromyelitis Optica
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Massachusetts General Hospital
- Principal Investigator
- Philippe-Antoine Bilodeau, MDMassachusetts General Hospital
- Intervention
- Rituximab (R)(drug)
- Enrollment
- 540 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2030
Study locations (3)
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Brigham and Women's Hospital, Boston, Massachusetts, United States
- Charité - Universitätsmedizin Berlin, Berlin, Germany
Collaborators
Patient-Centered Outcomes Research Institute · Charite University, Berlin, Germany · The Sumaira Foundation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07010302 on ClinicalTrials.govOther trials for Neuromyelitis Optica
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT05909761Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During PregnancyAmgen
- RECRUITINGPHASE3NCT05199688A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)Hoffmann-La Roche
- RECRUITINGPHASE4NCT07420296Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum DisorderTianjin Medical University General Hospital
- RECRUITINGNCT06885957Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSDTongji Hospital
- RECRUITINGPHASE1NCT06620809The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum DisordersTongji Hospital
- RECRUITINGNANCT06865274Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte Myelin Protein Antibody Disease, and Multiple Sclerosis.Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGNANCT06780709Impact of a Structured Wellness Behavioral Intervention on Quality of Life in NMOSDIcahn School of Medicine at Mount Sinai
- ACTIVE NOT RECRUITINGPHASE3NCT06724809Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSDAlexion Pharmaceuticals, Inc.